From the Research
Soquelitinib is currently not commercially available to patients and can only be accessed through participation in clinical trials. These trials are typically available at select cancer centers and research institutions, and patients interested in this medication would need to consult with their oncologist to determine if they might qualify for any ongoing clinical trials and where these trials are being conducted 1. The drug works by selectively inhibiting KRAS G12D mutations, which are common driver mutations in certain cancers, and has shown promising results in early studies, but it has not yet received FDA approval or been made available for general prescription use. Some key points to consider include:
- Soquelitinib is an experimental drug still in clinical trials for certain cancers, particularly non-small cell lung cancer with KRAS G12D mutations.
- The only way to access soquelitinib is through participation in clinical trials being conducted by Mirati Therapeutics (now part of Bristol Myers Squibb).
- Patients interested in this medication should consult with their oncologist to determine if they might qualify for any ongoing clinical trials and where these trials are being conducted.
- The drug has shown promising results in early studies, but it has not yet received FDA approval or been made available for general prescription use. It's also worth noting that while there are many studies on various topics related to cancer treatment, the most relevant and recent information on soquelitinib is crucial for making informed decisions about its availability and use 1.